Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
Nicolino Ruperto, Hermine I Brunner, Pierre Quartier, Tamàs Constantin, Nico M Wulffraat, Gerd Horneff, Ozgur Kasapcopur, Rayfel Schneider, Jordi Anton, Judith Barash, Reinhard Berner, Fabrizia Corona, Ruben Cuttica, Marine Fouillet-desjonqueres, Michel Fischbach, Helen E Foster, Dirk Foell, Sebastião C Radominski, Athimalaipet V Ramanan, Ralf Trauzeddel, Erbil Unsal, Jérémy Levy, Eleni Vritzali, Alberto Martini, Daniel J Lovell, On behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
Annals of the Rheumatic Diseases Dec 2018, 77 (12) 1710-1719; DOI: 10.1136/annrheumdis-2018-213150
